{"id":"W2142170680","doi":"10.1634/theoncologist.2011-0237","title":"Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Angiosarcoma; Medicine; Sorafenib; Sarcoma; Soft tissue sarcoma; Clinical endpoint; Internal medicine; Surgery; Toxicity; Oncology; Chemotherapy; Clinical trial; Pathology; Hepatocellular carcinoma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001669924,0.0008376841,0.0009187891,0.0002516425,0.0002058988,0.0004149806,0.0002681804,0.0004272503,0.002037353],"category_scores_gemma":[0.0005785043,0.0001815638,0.0009280953,0.0002185609,0.0003413772,0.0002546136,0.0002104344,0.0006912276,0.0002842915],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005343041,"about_ca_system_score_gemma":0.001329551,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001034597,"about_ca_topic_score_gemma":0.003749152,"domain_scores_codex":[0.9996667,0.0001957328,0.0000156358,0.00003783939,0.00003250931,0.00005156876],"domain_scores_gemma":[0.9996952,0.0000475312,0.00007087642,0.00001601302,0.00002683278,0.0001436018],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6417654,0.02544705,0.01823985,0.002030008,0.002676005,0.0004153405,0.0003728034,0.003335686,0.0353878,0.0006022083,0.009858915,0.259869],"study_design_scores_gemma":[0.7752931,0.1826897,0.03181595,0.00009691394,0.0006525864,0.0004361474,0.00004747567,0.0009958354,0.001257764,0.0002408545,0.006446041,0.00002762821],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889323,0.005874473,0.000409113,0.0007084479,0.00008455082,0.001789477,0.0005777777,0.00005224024,0.001571705],"genre_scores_gemma":[0.9877794,0.003675802,0.00182931,0.001132996,0.0002254237,0.001868464,0.001955279,0.00001189468,0.001521535],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002037353,"threshold_uncertainty_score":0.008831561,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02287312741647877,"score_gpt":0.2980100239155186,"score_spread":0.2751368964990398,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}